| Name | Title | Contact Details |
|---|
Public Sector Partners, Inc. is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our technology has been tested by top institutions and is used in hundreds of facilities throughout the world. We developed a technology that significantly reduces unhealthy contaminants. This technology quickly and effectively decreases airborne viruses, bacteria, particulates, mold, VOCs and odors. It cleans the air and creates a healthier environment.
Ascension is a faith-based healthcare organization dedicated to transformation through innovation across the continuum of care. As the largest non-profit health system in the U.S. and the world`s largest Catholic health system, Ascension is committed to delivering compassionate, personalized care to all, with special attention to persons living in poverty and those most vulnerable. In FY2016, Ascension provided more than $1.8 billion in care of persons living in poverty and other community benefit programs. Ascension includes approximately 160,000 associates and 36,000 aligned providers. Ascension`s Healthcare Division operates 2,500 sites of care – including 141 hospitals and more than 30 senior living facilities – in 24 states and the District of Columbia, while its Solutions Division provides a variety of services and solutions including physician practice management, venture capital investing, investment management, biomedical engineering, facilities management, clinical care management, information services, risk management, and contracting through Ascension`s own group purchasing organization.
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.
Babson Diagnostics is bringing medically-accurate blood testing to the pharmacy, and empowering people to take charge of their health by reimagining the entire blood testing process from ordering, collection, handling, analyzing, and reporting of results, making it less invasive and more convenient, accessible, and patient-centered.